Bionomics (BNOX) Stock Forecast, Price Target & Predictions
BNOX Stock Forecast
Bionomics stock forecast is as follows: an average price target of $6.00 (represents a 810.89% upside from BNOX’s last price of $0.66) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
BNOX Price Target
The average price target for Bionomics (BNOX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 810.89% upside from BNOX's last price of $0.66.
BNOX Analyst Ratings
According to 3 Wall Street analysts, Bionomics's rating consensus is 'Buy'. The analyst rating breakdown for BNOX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bionomics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 19, 2022 | Joshua Schimmer | Evercore ISI | $6.00 | $5.89 | 1.87% | 810.89% |
The latest Bionomics stock forecast, released on Dec 19, 2022 by Joshua Schimmer from Evercore ISI, set a price target of $6.00, which represents a 1.87% increase from the stock price at the time of the forecast ($5.89), and a 810.89% increase from BNOX last price ($0.66).
Bionomics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.66 | $0.66 | $0.66 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Bionomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bionomics's last price of $0.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 10, 2023 | Evercore ISI | - | Outperform | Upgrade |
| Dec 19, 2022 | William Blair | Outperform | Outperform | Hold |
Bionomics's last stock rating was published by H.C. Wainwright on Jun 13, 2024. The company gave BNOX a "Buy" rating, the same as its previous rate.
Bionomics Financial Forecast
Bionomics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $76.52K | $2.64M | $90.82K | $98.94K |
| High Forecast | $76.52K | $2.64M | $90.82K | $98.94K |
| Low Forecast | $76.52K | $2.64M | $90.82K | $98.94K |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
Bionomics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BNOX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Bionomics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | $-76.52K | $-2.64M | $-90.82K | $-98.94K |
| High Forecast | $-76.52K | $-2.64M | $-90.82K | $-98.94K |
| Low Forecast | $-76.52K | $-2.64M | $-90.82K | $-98.94K |
| Surprise % | - | - | - | - |
undefined analysts predict BNOX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionomics's previous annual EBITDA (undefined) of $NaN.
Bionomics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $21.75M | $-13.46M | $22.64M | $29.46M |
| High Forecast | $21.75M | $-13.46M | $22.64M | $29.46M |
| Low Forecast | $21.75M | $-13.46M | $22.64M | $29.46M |
| Surprise % | - | - | - | - |
Bionomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNOX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bionomics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | $362.30K | $12.52M | $429.98K | $468.42K |
| High Forecast | $362.30K | $12.52M | $429.98K | $468.42K |
| Low Forecast | $362.30K | $12.52M | $429.98K | $468.42K |
| Surprise % | - | - | - | - |
Bionomics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BNOX last annual SG&A of $NaN (undefined).
Bionomics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $2.29 | $-1.42 | $2.39 | $3.11 |
| High Forecast | $2.29 | $-1.42 | $2.39 | $3.11 |
| Low Forecast | $2.29 | $-1.42 | $2.39 | $3.11 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Bionomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNOX previous annual EPS of $NaN (undefined).
Bionomics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| BNOX | Bionomics | $0.66 | $6.00 | 809.09% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
BNOX Forecast FAQ
Is Bionomics a good buy?
Yes, according to 3 Wall Street analysts, Bionomics (BNOX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BNOX's total ratings.
What is BNOX's price target?
Bionomics (BNOX) average price target is $6 with a range of $6 to $6, implying a 810.89% from its last price of $0.659. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bionomics stock go up soon?
According to Wall Street analysts' prediction for BNOX stock, the company can go up by 810.89% (from the last price of $0.659 to the average price target of $6), up by 810.89% based on the highest stock price target, and up by 810.89% based on the lowest stock price target.
Can Bionomics stock reach $1?
BNOX's average twelve months analyst stock price target of $6 supports the claim that Bionomics can reach $1 in the near future.
What are Bionomics's analysts' financial forecasts?
BNOX's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $2.83M (high $2.83M, low $2.83M), average EBITDA is $-2.834M (high $-2.834M, low $-2.834M), average net income is $38.64M (high $38.64M, low $38.64M), average SG&A $13.42M (high $13.42M, low $13.42M), and average EPS is $4.07 (high $4.07, low $4.07).